Histologically defined intratumoral sequencing uncovers evolutionary cues into conserved molecular events driving gliomagenesis

Neuro-Oncology

Volumn 19, Issue 12, 2017, Pages 1599-1606

  Prabhu, Antony ^a   Kesarwani, Pravin ^a   Kant, Shiva ^a   Graham, Stewart F ^b   Chinnaiyan, Prakash ^a  

^a Beaumont Research Institute   (United States)

^b Metabolomics and Obstetrics Gynecology   (United States)

Author keywords

glioblastoma; next generation sequencing; tumor evolution; tumor heterogeneity

Indexed keywords

RNA; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC CONSERVATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; LASER CAPTURE MICRODISSECTION; MESENCHYME CELL; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; X-RAY COMPUTED TOMOGRAPHY; BRAIN TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR EVOLUTION; PATHOLOGY; PROCEDURES; PROGNOSIS;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; EVOLUTION, MOLECULAR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 85040059826     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nox100     Document Type: Article

References (42)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492-507.
2. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
3. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.
4. TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
5. Verhaak RG, Hoadley KA, Purdom E, et al.; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
6. Guan X, Vengoechea J, Zheng S, et al. Molecular subtypes of glioblastoma are relevant to lower grade glioma. PLoS One. 2014;9(3):e91216.
7. Ozawa T, Riester M, Cheng YK, et al. Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014;26(2):288-300.
8. Meyer M, Reimand J, Lan X, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A. 2015;112(3):851-856.
9. Parker NR, Hudson AL, Khong P, et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016;6:22477.
10. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396-1401.
11. Allen Institute for Brain Science. Ivy Glioblastoma Atlas Project. 2015. Available from: glioblastoma.alleninstitute.org.
12. Puchalski R, Shah N, Miller J, et al. GENO-32. An anatomic transcriptional atlas of glioblastoma. Neuro Oncol. 2015;17(suppl 5):v99.
13. Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Res. 2015;43(W1):W251-W257.
14. Tsigelny IF, Kouznetsova VL, Lian N, Kesari S. Molecular mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget. 2016;7(33):53074-53101.
15. Soroceanu L, Kharbanda S, Chen R, et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A. 2007;104(9):3466-3471.
16. Pachow D, Wick W, Gutmann DH, Mawrin C. The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol. 2015;17(2):189-199.
17. Sarcar B, Kahali S, Prabhu AH, et al. Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther. 2011;10(12):2405-2414.
18. Barbagallo D, Condorelli A, Ragusa M, et al. Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme. Oncotarget. 2016;7(4):4746-4759.
19. Wang Z, Yang J, Xu G, et al. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Oncotarget. 2015;6(5):3147-3164.
20. Matsuda Y, Miura K, Yamane J, et al. SERPINI1 regulates epithelialmesenchymal transition in an orthotopic implantation model of colorectal cancer. Cancer Sci. 2016;107(5):619-628.
21. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005;7(2):122-133.
22. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004;5:27.
23. Said HM, Polat B, Staab A, et al. Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. Oncol Rep. 2008;20(2):413-419.
24. Sullivan JP, Nahed BV, Madden MW, et al. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014;4(11):1299-1309.
25. Babapoor-Farrokhran S, Jee K, Puchner B, et al. Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. Proc Natl Acad Sci U S A. 2015;112(23):E3030-E3039.
26. Hu K, Babapoor-Farrokhran S, Rodrigues M, et al. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget. 2016;7(7):7816-7828.
27. Wang D, Berglund A, Kenchappa RS, Forsyth PA, Mulé JJ, Etame AB. BIRC3 is a novel driver of therapeutic resistance in glioblastoma. Sci Rep. 2016;6:21710.
28. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313-326.
29. Conroy S, Wagemakers M, Walenkamp AM, Kruyt FA, den Dunnen WF. Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses. J Neurooncol. 2017;131(1):11-20.
30. Mathew LK, Skuli N, Mucaj V, et al. miR-218 opposes a critical RTKHIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A. 2014;111(1):291-296.
31. Cooper LA, Gutman DA, Chisolm C, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. Am J Pathol. 2012;180(5):2108-2119.
32. Lloyd MC, Cunningham JJ, Bui MM, Gillies RJ, Brown JS, Gatenby RA. Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Res. 2016;76(11):3136-3144.
33. Chinnaiyan P, Kensicki E, Bloom G, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012;72(22):5878-5888.
34. Eikawa S, Ohue Y, Kitaoka K, et al. Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6-and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol. 2010;185(11):6734-6740.
35. Boado RJ, Black KL, Pardridge WM. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res. 1994;27(1):51-57.
36. Nishioka T, Oda Y, Seino Y, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res. 1992;52(14):3972-3979.
37. Michelakis ED, Sutendra G, Dromparis P, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra34.
38. Prabhu A, Sarcar B, Miller CR, et al. Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis. Neuro Oncol. 2015;17(9):1220-1230.
39. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12(7):487-493.
40. Enriquez-Navas PM, Kam Y, Das T, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8(327):327ra24.
41. Nichol D, Jeavons P, Fletcher AG, et al. Steering evolution with sequential therapy to prevent the emergence of bacterial antibiotic resistance. PLoS Comput Biol. 2015;11(9):e1004493.
42. Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA. Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012;72(24):6362-6370.